A prostate biopsy risk calculator based on MRI : development and comparison of the Prospective Loyola University multiparametric MRI (PLUM) and Prostate Biopsy Collaborative Group (PBCG) risk calculators
BJU International · 2023-02 · 131 (2) · 227-235
DOI: 10.1111/bju.15835 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJU International, online erschienen am 11.07.2022. Verfasst von Hiten D Patel und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Loyola University Medical Center, Maywood, IL, USA. Hauptthemen laut MEDLINE: Multiparametric Magnetic Resonance Imaging, Prostatic Neoplasms. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, Comprehensive Cancer Center, University of Alabama at Birmingham, Siemens Medical Solutions USA.
Abstract (Originalsprache)
Objectives
To develop and validate a prostate cancer (PCa) risk calculator (RC) incorporating multiparametric magnetic resonance imaging (mpMRI) and to compare its performance with that of the Prostate Biopsy Collaborative Group (PBCG) RC. Patients and Methods Men without a PCa diagnosis receiving mpMRI before biopsy in the Prospective Loyola University mpMRI (PLUM) Prostate Biopsy Cohort (2015–2020) were included. Data from a separate institution were used for external validation. The primary outcome was diagnosis of no cancer, grade group (GG)1 PCa, and clinically significant (cs)PCa (≥GG2). Binary logistic regression was used to explore standard clinical and mpMRI variables (prostate volume, Prostate Imaging‐Reporting Data System [PI‐RADS] version 2.0 lesions) with the final PLUM RC, based on a multinomial logistic regression model. Receiver‐operating characteristic curve, calibration curves, and decision‐curve analysis were evaluated in the training and validation cohorts.
Results
A total of 1010 patients were included for development ( N = 674 training [47.8% PCa, 30.9% csPCa], N = 336 internal validation) and 371 for external validation. The PLUM RC outperformed the PBCG RC in the training (area under the curve [AUC] 85.9% vs 66.0%; P < 0.001), internal validation (AUC 88.2% vs 67.8%; P < 0.001) and external validation (AUC 83.9% vs 69.4%; P < 0.001) cohorts for csPCa detection. The PBCG RC was prone to overprediction while the PLUM RC was well calibrated. At a threshold probability of 15%, the PLUM RC vs the PBCG RC could avoid 13.8 vs 2.7 biopsies per 100 patients without missing any csPCa. At a cost level of missing 7.5% of csPCa, the PLUM RC could have avoided 41.0% (566/1381) of biopsies compared to 19.1% (264/1381) for the PBCG RC. The PLUM RC compared favourably with the Stanford Prostate Cancer Calculator (SPCC; AUC 84.1% vs 81.1%; P = 0.002) and the MRI‐European Randomized Study of Screening for Prostate Cancer (ERSPC) RC (AUC 84.5% vs 82.6%; P = 0.05).
Conclusions
The mpMRI‐based PLUM RC significantly outperformed the PBCG RC and compared favourably with other mpMRI‐based RCs. A large proportion of biopsies could be avoided using the PLUM RC in shared decision making while maintaining optimal detection of csPCa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Loyola University Medical Center, Maywood, IL, USA.
- Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
- Department of Radiology, Loyola University Medical Center, Maywood, IL, USA.
- Department of Urology, University of Alabama at Birmingham, Birmingham, AL, USA.
- Department of Radiology, University of Alabama at Birmingham, Birmingham, AL, USA.
- O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA.
ORCID-Profile: Hiten D Patel, Soroush Rais-Bahrami
Förderung
- NCI NIH HHS
- Comprehensive Cancer Center, University of Alabama at Birmingham
- Siemens Medical Solutions USA
- National Cancer Institute
Zitieren
APA
Patel, H. D., Koehne, E. L., Shea, S. M., Fang, A. M., Gerena, M., Gorbonos, A., Quek, M. L., Flanigan, R. C., Goldberg, A., Rais-Bahrami, S., & Gupta, G. N. (2023). A prostate biopsy risk calculator based on MRI : development and comparison of the Prospective Loyola University multiparametric MRI (PLUM) and Prostate Biopsy Collaborative Group (PBCG) risk calculators. BJU International, 131(2), 227-235. https://doi.org/10.1111/bju.15835
Vancouver
Patel HD, Koehne EL, Shea SM, Fang AM, Gerena M, Gorbonos A, et al. A prostate biopsy risk calculator based on MRI : development and comparison of the Prospective Loyola University multiparametric MRI (PLUM) and Prostate Biopsy Collaborative Group (PBCG) risk calculators. BJU International. 2023;131(2):227-235. doi:10.1111/bju.15835
BibTeX
@article{Patel2023,
author = {Patel, Hiten D and Koehne, Elizabeth L and Shea, Steven M and Fang, Andrew M and Gerena, Marielia and Gorbonos, Alex and Quek, Marcus L and Flanigan, Robert C and Goldberg, Ari and Rais-Bahrami, Soroush and Gupta, Gopal N},
title = {A prostate biopsy risk calculator based on MRI : development and comparison of the Prospective Loyola University multiparametric MRI (PLUM) and Prostate Biopsy Collaborative Group (PBCG) risk calculators},
journal = {BJU International},
year = {2023},
volume = {131},
number = {2},
pages = {227--235},
doi = {10.1111/bju.15835}
}
EUVIMED